Pharmaceuticals Sector - Solvay

More documents

Recommendations

Info

102 Solvay Global Annual Report 2005 TURKEY Arili Plastik Sanayii AS, Pendik RUSSIA 50 Pl Soligran ZAO, Moscou UNITED STATES 50 Pl Inergy Automotive Systems Holding (USA), Troy, MI 50 Pl Inergy Automotive Systems (USA) LLC, Troy, MI 50 Pl Pipelife Jet Stream, Inc. Siloam Springs, AR CANADA 50 Pl Inergy Automotive Systems (Canada), Inc., Blenheim MEXICO 50 Pl Inergy Automotive Systems Mexico S.A. de C.V., Ramos 50 Pl Solvay & CPC Barium Strontium Reynosa S. de R.L. de C.V., Reynosa 75 Ch Solvay & CPC Barium Strontium Monterrey S. de R.L. de C.V., Monterrey BRAZIL 75 Ch Dacarto Benvic S.A., Santo André 50 Pl Peroxidos do Brasil Ltda, Sao Paulo 69.4 Ch Inergy Automotive Systems Brazil Ltda, Sao Paulo ARGENTINA 50 Pl Inergy Automotive Systems Argentina S.A., Buenos Aires CHINA 50 Pl Changzhou Pipelife Reinforced Plastic C° Ltd, Changzhou 32.5 Pl Chengdu Chuanwie Plastic Pipe Co. Ltd, Longquanyi District 45 Pl Pipelife (Guangzhou) Plastic Pipe Mfg Ltd, Nansha 50 Pl Sichuan Chuanxi Plastic Co. Ltd, Xipu Pixian County THAILAND 25.5 Pl Inergy Automotive Systems Thailand Ltd, Bangkok 50 Pl Vinythai Public Company Ltd, Bangkok SOUTH KOREA 48.5 Pl Solvay & CPC Barium Strontium Korea Co Ltd, Onsan 75 Ch Daehan Specialty Chemicals Co., Ltd, Seoul 60 Ch Inergy Automotive Systems Co., Ltd, Kyungju JAPAN 50 Pl Inergy Automotive Systems KK, Tokyo SOUTH AFRICA 50 Pl Inergy Automotive Systems South Africa (Pty) Ltd, Brits VIRGIN ISLANDS 50 Pl Pipelife Holding (HK) Ltd, Tortola 50 Pl
Summary fi nancial statements of Solvay S.A. The annual fi nancial statements of Solvay S.A. are presented in summary format below. In accordance with the Companies Code, the annual fi nancial statements of Solvay S.A., the management report and the statutory auditor’s report will be deposited with the National Bank of Belgium. These documents are also available on request from: Solvay S.A. Rue du Prince Albert 33 B -1050 Brussels The Statutory Auditor has expressed a reserve with regard to the decision, mentioned in the management report, to maintain the value of Solvay Pharmaceuticals Sàrl at the historical value of the participating investments contributed to it. The reserve relates solely to the accounts of Solvay S.A. and does not in any way concern the Group’s consolidated accounts. Balance sheet of Solvay S.A. EUR million at December 31 ASSETS 2004 2005 Fixed assets 4 350 3 385 Start-up expenses and intangible assets 69 69 Tangible assets 90 66 Financial assets 4 191 3 250 Current assets 2 550 2 782 Inventories 21 15 Trade receivables 134 121 Other receivables 870 1 485 Short-term investments and cash equivalents 1 525 1 161 Total assets SHAREHOLDERS’ EQUITY AND LIABILITIES 6 900 6 167 Shareholders’ equity 3 594 3 765 Capital 1 269 1 270 Other equity 1 962 1 966 Net income carried forward 363 529 Investment grants Provisions and deferred taxes 337 356 Financial debt 2 532 1 578 - due in more than one year 1 517 815 - due within one year 1 015 763 Trade liabilities 91 120 Other liabilities 346 348 Total shareholders’ equity and liabilities 6 900 6 167 103 Solvay Global Annual Report 2005
Page 1 and 2:
Driven by the future Growth, Compet
Page 3 and 4:
Highlights January 2005 Solvay fi n
Page 5 and 6:
Activities Group sales 2005 = EUR 8
Page 7 and 8:
Our Vision - Independent industrial
Page 9 and 10:
here to stay, in our view irreversi
Page 11 and 12:
Board of Directors and Corporate Go
Page 13 and 14:
4 Executive Committee and General M
Page 15 and 16:
Such a strategy is possible only wi
Page 17 and 18:
Specialities Solvay Specialties fro
Page 19 and 20:
Key fi gures [EUR million] Pharmace
Page 21 and 22:
Cardiometabolic Cardiovascular dise
Page 23 and 24:
Cardiometabolics Fenofi brate, TRIC
Page 25 and 26:
“ DUODOPA® entered Solvay’s pr
Page 27 and 28:
Pharmaceuticals Sector Therapeutic
Page 29 and 30:
Key fi gures [EUR million] Chemical
Page 31 and 32:
Growth To speed up its growth, the
Page 33 and 34:
Initiatives have also been launched
Page 35 and 36:
“ The ‘Soil Remediation Reagent
Page 37 and 38:
Key fi gures [EUR million] Plastics
Page 39 and 40:
Innovation “Twin-Sheet Blow Mould
Page 41 and 42:
Plastics 37 Solvay Global Annual Re
Page 43 and 44:
which it was able to take advantage
Page 45 and 46:
New Business Development Priority t
Page 47 and 48:
Meeting The Science Days organized
Page 49 and 50:
Human Resources The Group’s fi ve
Page 51 and 52:
“ At the end of this seminar, all
Page 53 and 54:
Sustainable Development 2005 saw th
Page 55 and 56: Accident frequency rate Persons wor
Page 57 and 58: Management Report New records for S
Page 59 and 60: Expenditure on the future by Sector
Page 61 and 62: Financial Statements The following
Page 63 and 64: Consolidated balance sheet EUR mill
Page 65 and 66: IFRS valuation rules The main accou
Page 67 and 68: 9. Impairment Every year the Group
Page 69 and 70: Notes to the fi nancial statements
Page 71 and 72: (2) Financial data by region These
Page 73 and 74: and the estimated fi nancial conseq
Page 75 and 76: The deferred taxes recorded in the
Page 77 and 78: 2005 Millions EUR Acquisitions Disp
Page 79 and 80: Neopharma On January 19, 2005 the S
Page 81 and 82: (around 300 persons) with a view to
Page 83 and 84: In 2005 the impairment tests on goo
Page 85 and 86: Solvay Group purchased 100% of the
Page 87 and 88: Post-employment benefi t plans are
Page 89 and 90: Actuarial assumptions used in deter
Page 91 and 92: Analysis of total fi nancial debt b
Page 93 and 94: In this way, at the end of 2005, th
Page 95 and 96: The following amounts relating to J
Page 97 and 98: PORTUGAL Fournier Farmaceutica Port
Page 99 and 100: List of fully consolidated Group co
Page 101 and 102: Solvay Salz Holding GmbH, Hannover
Page 103 and 104: CANADA Fournier Pharma, Inc., Montr
Page 105: GREAT BRITAIN Inergy Automotive Sys
Page 109 and 110: Statutory auditor’s report to the
Page 111 and 112: The Solvay share compared with the
Page 113 and 114: Contacts: The Investor Relations Te
Page 115 and 116: Shareholders’ Diary - May 9, 2006
show all

Pharmaceuticals Sector - Solvay

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?